In Vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin

Journal of Chemotherapy

Volumn 14, Issue 6, 2002, Pages 584-590

  Novelli, Andrea ^a,b   Fallani, S ^a   Cassetta, M I ^a   Arrigucci, S ^a   Mazzei, T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Clarithromycin; Erythromycin; Pharmacodynamics

Indexed keywords

CLARITHROMYCIN; ERYTHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; EVALUATION; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONITIS; PHARMACODYNAMICS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL;

EID: 0036975207     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2002.14.6.584     Document Type: Article

References (28)

1. th ed., New York. The McGraw-Hill Companies; 1996:1-2.
2. Craig W. Post-antibiotic effects in experimental infection models: relationship to in vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993; 31: 149-158.
3. Craig W. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
4. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
5. Li RC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999; 37: 1-16.
6. Periti P, Mazzei T. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. J Chemother 1999; 11: 11-27.
7. den Hollander JG, Knudsen JD, Mouton JW, Fuursted K, Frimodt-Moller N, Verbrugh HA, Espersen F. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. Antimicrob Agents Chemother 1998; 42: 377-82.
8. Azoulay-Dupuis E, Vallee E, Bedos JP, Muffat-Joly M, Pocidalo JJ. Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother 1991; 35 (6): 1024-8.
9. Ishida K, Kaku M, Irifune K, et al. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994; 38: 790-798.
10. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. Villanova, PA, 1997.
11. Mazzei T, Surrenti C, Novelli A, et al. Pharmacokinetics of dirithromycin in patients with mild or moderate cirrhosis. Antimicrob Agents Chemother 1999; 43 (7): 1556-9.
12. Hintze JL. Number Cruncher Statistical System (NCCS) Ver 5.03 1992.
13. nd ed. Marcel Dekker, New York 1982.
14. Craig WA, Gudmundsson S. The postantibiotic effect, In V. Lorian (ed): Antibiotics in Laboratory Medicine. Third Ed. The Williams & Wilkins, Co, Baltimore. 1991: 403-431.
15. Girard AE, Cimochowski CR, Faiella JA. The comparative activity of azithromycin, macrolides and amoxycillin against streptococci in experimental infections. J Antimicrob Chemother 1993; 31 Suppl E: 29-37.
16. Veber B, Vallee E, Desmonts JM, Pocidalo JJ, Azoulay-Dupuis E. Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia. J Antimicrob Chemother 1993; 32 (3): 473-82.
17. Tissi L, von Hunolstein C, Mosci P, Campanelli C, Bistoni F, Orefici G. In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G. Antimicrob Agents Chemother 1995; 39 (9): 1938-47.
18. Ono T, Numata K, Nagate T, Mitsuhashi S, Inoue M. In vitro and in vivo antibacterial activities of clarithromycin. Chemotherapy 1996; 42 (3): 159-69.
19. Tessier PR, Kim MK, Zhou W, et al. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 2002; 46 (5): 1425-1434.
20. Parazzoli A, Petrone M, Broglio R, Marturana MB, Di Modugno E. Time- or concentration-dependent efficacy of clarithromycin using S. pneumoniae strains with different phenotypes. Abst 5.07. The Sixth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones - Bologna, Italy January 23-25, 2002.
21. Comber KR, Osborne CD, Sutherland R. Comparative effects of amoxycillin and ampicillin in the treatment of experimental mouse infections. Antimicrob Agents Chemother 1975; 7 (2): 179-85.
22. Cleeland R, Squires E. Evaluation of new antimicrobials in vitro and in experimental animal infections In: V. Lorian (ed): Antibiotics in Laboratory Medicine. Third Ed., The Williams & Wilkins Co., Baltimore. 1991: 739-786.
23. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159 (2): 281-92.
24. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998; 42 (9): 2375-9.
25. Chu S, Wilson DS, Deaton RL, Mackenthun AV, Eason CN, Cavanaugh JH. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 1993; 33: 719-726.
26. Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 1997; 16: 438-443.
27. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15 (3): 255-9.
28. Novelli A, Fallani S, Cassetta MI, Conti S, Mazzei T. In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin Abst 997. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy - San Francisco, CA September 28- October 1, 1999.